Sign in to view content

Prophylaxis Intravitreal Aflibercept Against Conversion to Neovascular AMD in High-Risk Eyes (PRO-CON): 24-Month Results

Jeffrey S. Heier, MD

Video
Published 2019

Jeffrey S. Heier, MD

AMD Non-neovascular Symposium

Related

96-Week Visual and Expanded Anatomical Outcomes of Brolucizumab Versus Aflibercept in Patients With nAMD: Results From HAWK and HARRIER
Chirag D. Jhaveri, MD, FASRS
Annual Meeting Talks
2019
Patients Ultra-Responsive to Ranibizumab (RBZ): Rates of Great Than or Equal to 4-Step Improvement in Diabetic Retinopathy Severity in DRCR.net Protocol S
Allen Chiang, MD, FASRS
Annual Meeting Talks
2019
Differences in Intravitreal Silicone Oil Following Multiple Bevacizumab, Ranibizumab, and Aflibercept Injections
John T. Thompson, MD
Annual Meeting Talks
2019

Category: AMD-Non-Neovascular

See more